High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with <i>EGFR</i>-mutant lung cancer cellsShigeki Nanjo, Seiji Yano|Oncotarget|2015Cited by 58
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancerShigeki Nanjo, Trever G. Bivona|Journal of Clinical Investigation|2022Cited by 53
Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR InhibitorsShigeki Nanjo, Seiji Yano|PLoS ONE|2013Cited by 44
<i>In vivo</i> imaging models of bone and brain metastases and pleural carcinomatosis with a novel human <i><scp>EML</scp>4‐<scp>ALK</scp></i> lung cancer cell lineShigeki Nanjo, Seiji Yano|Cancer Science|2015Cited by 34
Circulating tumor DNA analysis in patients with EGFR mutant lung cancerShigeki Nanjo, Trever G. Bivona|Journal of Thoracic Disease|2018Cited by 2